Skip to content

Merve Akan

3 papers in the library · 19 citations · publishing 2023-2026

Papers

Sort Most recent Most cited

Oxa-noribogaine reduces alcohol drinking through aversion learning and by altering glutamatergic activity in the mPFC

Research Square March 31, 2026 Marcus W. Meinhardt, Ivan Skorodumov, Florian Walter et al. preprint

Abstract Alcohol use disorder is a major global health problem, and current treatments often fail to produce lasting reductions in harmful drinking1,2. Psychedelic-assisted therapies may promote durable behavioural change by enhancing brain plasticity during emotionally meaningful experiences, but progress has been limited by a lack of experimental models that capture these context-dependent...

Psychedelic therapy in depression and substance use disorders

European Journal of Neuroscience May 21, 2024 Nur Damla Korkmaz, Ugur Cikrikcili, Merve Akan et al. 19 citations

Abstract Psychoactive substances obtained from botanicals have been applied for a wide variety of purposes in the rituals of different cultures for thousands of years. Classical psychedelics from N,N′‐dimethyltryptamine, psilocybin, mescaline and various lysergamides cause specific alterations in perception, emotion and cognition by acting through serotonin 5‐HT 2A receptor activation. Lysergic...

A shea butter-based ketamine ointment: The antidepressant effects of transdermal ketamine in rats.

Behavioural Brain Research July 22, 2023 Merve Akan, Ivan Skorodumov, M. Meinhardt et al.

The delayed onset of monoaminergic antidepressants and disadvantages of traditional administration routes created the need for alternative non-invasive delivery methods with rapid onset therapeutic effect. Ketamine attracted attention as a fast-acting glutamatergic antidepressant with ideal physiochemical properties for alternative routes of administration. However, there is no sufficient data...